110 related articles for article (PubMed ID: 8603446)
1. Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice.
Eiseman JL; Yuan ZM; Eddington ND; Sentz DL; Callery PS; Egorin MJ
Cancer Chemother Pharmacol; 1996; 38(1):13-20. PubMed ID: 8603446
[TBL] [Abstract][Full Text] [Related]
2. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats.
Egorin MJ; Lagattuta TF; Hamburger DR; Covey JM; White KD; Musser SM; Eiseman JL
Cancer Chemother Pharmacol; 2002 Jan; 49(1):7-19. PubMed ID: 11855755
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and tissue distribution in CD2F1 mice of Pc4 (NSC 676418), a silicone phthalocyanine photodynamic sensitizing agent.
Egorin MJ; Zuhowski EG; Sentz DL; Dobson JM; Callery PS; Eiseman JL
Cancer Chemother Pharmacol; 1999; 44(4):283-94. PubMed ID: 10447575
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats.
Stecklair KP; Hamburger DR; Egorin MJ; Parise RA; Covey JM; Eiseman JL
Cancer Chemother Pharmacol; 2001 Nov; 48(5):375-82. PubMed ID: 11761455
[TBL] [Abstract][Full Text] [Related]
6. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats.
Egorin MJ; Yuan ZM; Sentz DL; Plaisance K; Eiseman JL
Cancer Chemother Pharmacol; 1999; 43(6):445-53. PubMed ID: 10321503
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
8. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and antitumor properties in tumor-bearing mice of an enediol analogue inhibitor of glyoxalase I.
Sharkey EM; O'Neill HB; Kavarana MJ; Wang H; Creighton DJ; Sentz DL; Eiseman JL
Cancer Chemother Pharmacol; 2000; 46(2):156-66. PubMed ID: 10972486
[TBL] [Abstract][Full Text] [Related]
10. Plasma pharmacokinetics, bioavailability, and tissue distribution in CD2F1 mice of halomon, an antitumor halogenated monoterpene isolated from the red algae Portieria hornemannii.
Egorin MJ; Sentz DL; Rosen DM; Ballesteros MF; Kearns CM; Callery PS; Eiseman JL
Cancer Chemother Pharmacol; 1996; 39(1-2):51-60. PubMed ID: 8995499
[TBL] [Abstract][Full Text] [Related]
11. Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Kestell P; Paxton JW; Rewcastle GW; Dunlop I; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):323-30. PubMed ID: 10071984
[TBL] [Abstract][Full Text] [Related]
12. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
[TBL] [Abstract][Full Text] [Related]
13. Absorption, protein binding, pharmacokinetics and excretion of the anti-ischemic and anti-hypertensive arylpiperazine derivative CDRI-93/478 in rats.
Lal J; Gupta RC
Arzneimittelforschung; 2008; 58(2):62-70. PubMed ID: 18412019
[TBL] [Abstract][Full Text] [Related]
14. Preclinical pharmacology of ecteinascidin 729, a marine natural product with potent antitumor activity.
Reid JM; Walker DL; Ames MM
Cancer Chemother Pharmacol; 1996; 38(4):329-34. PubMed ID: 8674155
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 2-chloro-2'-deoxyadenosine administered subcutaneously or by continuous intravenous infusion.
Sonderegger T; Betticher DC; Cerny T; Lauterburg BH
Cancer Chemother Pharmacol; 2000; 46(1):40-2. PubMed ID: 10912576
[TBL] [Abstract][Full Text] [Related]
16. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and pharmacokinetics of N1,N14-diethylhomospermine.
Bergeron RJ; Weimar WR; Luchetta G; Sninsky CA; Wiegand J
Drug Metab Dispos; 1996 Mar; 24(3):334-43. PubMed ID: 8820425
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor 2,2,2-trifluoro-1-(3-trimethylsilylphenyl) ethanone in dog. Potential for transdermal patch delivery.
Dow J; Dulery BD; Hornsperger JM; Di Francesco GF; Keshary P; Haegele KD
Arzneimittelforschung; 1995 Dec; 45(12):1245-52. PubMed ID: 8595078
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetics and bioavailability of noscapine, a tubulin-binding anticancer agent.
Aneja R; Dhiman N; Idnani J; Awasthi A; Arora SK; Chandra R; Joshi HC
Cancer Chemother Pharmacol; 2007 Nov; 60(6):831-9. PubMed ID: 17285314
[TBL] [Abstract][Full Text] [Related]
20. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human alpha1-acid glycoprotein binding.
Hedaya MA; Daoud SS
Anticancer Res; 2001; 21(6A):4005-10. PubMed ID: 11911284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
